Cargando…
Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606893/ https://www.ncbi.nlm.nih.gov/pubmed/34819851 http://dx.doi.org/10.3389/fphar.2021.668952 |
_version_ | 1784602435520561152 |
---|---|
author | Chen, Xiao Wang, Dongdong Wang, Guangfei Huang, Yidie Yu, Xin Lu, Jinmiao Zhai, Xiaowen Xu, Hong Li, Zhiping |
author_facet | Chen, Xiao Wang, Dongdong Wang, Guangfei Huang, Yidie Yu, Xin Lu, Jinmiao Zhai, Xiaowen Xu, Hong Li, Zhiping |
author_sort | Chen, Xiao |
collection | PubMed |
description | Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future. |
format | Online Article Text |
id | pubmed-8606893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86068932021-11-23 Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma Chen, Xiao Wang, Dongdong Wang, Guangfei Huang, Yidie Yu, Xin Lu, Jinmiao Zhai, Xiaowen Xu, Hong Li, Zhiping Front Pharmacol Pharmacology Sirolimus is an effective oral treatment for pediatric patients with lymphangioma. The present clinical study in 15 children (0.12–16.39 years of age) examines the effects of underlying factors on sirolimus concentrations through application of a population pharmacokinetic model. Using Monte Carlo simulation, an initial dose regimen for sirolimus in pediatric patients with lymphangioma is presented. It is found that the lower the body weight, the higher the clearance rate and sirolimus clearances are 0.31–0.17 L/h/kg in pediatric patients with lymphangioma whose weights are 5–60 kg, respectively. The doses of sirolimus, 0.07, 0.06, 0.05 mg/kg/day are recommended for weights of 5–10, 10–24.5 and 24.5–60 kg in children with lymphangioma. This study is the first to establish a population pharmacokinetic model for sirolimus and to recommend initial doses in pediatric patients with lymphangioma. Large scale, prospective studies are needed in the future. Frontiers Media S.A. 2021-11-08 /pmc/articles/PMC8606893/ /pubmed/34819851 http://dx.doi.org/10.3389/fphar.2021.668952 Text en Copyright © 2021 Chen, Wang, Wang, Huang, Yu, Lu, Zhai, Xu and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Xiao Wang, Dongdong Wang, Guangfei Huang, Yidie Yu, Xin Lu, Jinmiao Zhai, Xiaowen Xu, Hong Li, Zhiping Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
title | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
title_full | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
title_fullStr | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
title_full_unstemmed | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
title_short | Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma |
title_sort | optimization of initial dose regimen for sirolimus in pediatric patients with lymphangioma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606893/ https://www.ncbi.nlm.nih.gov/pubmed/34819851 http://dx.doi.org/10.3389/fphar.2021.668952 |
work_keys_str_mv | AT chenxiao optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT wangdongdong optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT wangguangfei optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT huangyidie optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT yuxin optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT lujinmiao optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT zhaixiaowen optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT xuhong optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma AT lizhiping optimizationofinitialdoseregimenforsirolimusinpediatricpatientswithlymphangioma |